Andrew Wasson

Partner

Publications

  • Revisiting the Debate on an Orange Book for the Biologics Price Competition and Innovation Act, FOOD AND DRUG LAW INSTITUTE UPDATE 48 (July/August 2011)
  • Should FDA Undertake More than a “Ministerial” Role with respect to Patent Information, 1(4) FDLI’S FOOD AND DRUG POLICY FORUM (February 23, 2011) (with Brian J. Malkin)
  • Disentangling Biobetters under the Biologics Price Competition and Innovation Act of 2009, FOOD AND DRUG LAW INSTITUTE UPDATE 60 (January/February 2011) (with Brian J. Malkin)
  • Biosimilars Are a Reality: Key Features of the Biologics Price Competition and Innovation Act, FOOD AND DRUG LAW INSTITUTE UPDATE 6 (May/June 2010) (with Brian J. Malkin)
  • Kokona et al., Probing the Oligomeric Assemblies of Pea Porphobilinogen Synthase by Analytical Ultracentrifugation, 47(40) BIOCHEMISTRY 10649 (Oct. 2009) (co-author)
  • Taking Biologics for Granted? Takings, Trade Secrets, and Off-Patent Biological Products, 2005 DUKE L. & TECH. REV. 0004 (2005)
  • Protecting the Next Small Thing: Nanotechnology and the Reverse Doctrine of Equivalents, 2004 DUKE L. & TECH. REV. 0010 (2004)
  • A Reflection on Rulemaking: The Rule 11 Experience, 37 LOY. LA. L. REV. 563 (2004) (with Professor Paul D. Carrington)
  • Breinig et al., Control of Tetrapyrrole Biosynthesis by Alternate Quaternary Forms of Porphobilinogen Synthase, 10 NAT. STRUCT. BIOL. 757 (Sept. 2003) (co-author)

Speaking Engagements

  • Third Party IP: Preserving Freedom to Operate, Food and Drug Law Institute, Intellectual Property Throughout the Drug Development Lifecycle (July 7, 2012).
  • First-filed Generic Exclusivity and Forfeiture Thereof, New Jersey Intellectual Property Law Association, 25th Annual Pharmaceutical / Chemical Patent Practice Update (Dec. 7, 2011).

Awards

  • SuperLawyers® Metro Edition, 2013 Rising Stars